Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
34 hedge funds and large institutions have $2.41M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 5 closing their positions.
83% more call options, than puts
Call options by funds: $275K | Put options by funds: $150K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 31 → 34 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less capital invested
Capital invested by funds: $3.58M → $2.41M (-$1.17M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$339K |
| 2 |
Morgan Stanley
New York
|
+$336K |
| 3 |
Renaissance Technologies
New York
|
+$240K |
| 4 |
VF
Virtu Financial
New York
|
+$198K |
| 5 |
Jane Street
New York
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$118K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$47.8K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$40K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$32K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$24.2K |
NBRV Hedge Fund Activity: Q4 2021 in Review
34 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2021, worth a combined $2.41M — down 33% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NBRV positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $339K. The largest seller was Millennium Management, exiting entirely with an estimated $118K sold.
- 34 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2021, up from 31 in Q3 2021.
- Funds reported $2.41M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2021, down 33% quarter-over-quarter.
- 8 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2021 and 5 closed out, a net change of +3 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2021 was GSA Capital Partners, an estimated $339K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2021 was Millennium Management, an estimated $118K sold.
Based on aggregated 13F filings for Q4 2021.